Consensus and controversies in platelet transfusion

Gaydos, 1962, The quantitative relationship between platelet count and hemorrhage in patients with acute leukemia, N Engl J Med, 266, 905, 10.1056/NEJM196205032661802 Djerass, 1963, Transfusions of fresh platelet concentrates to patients with secondary thrombocytopenia, N Engl J Med, 268, 221, 10.1056/NEJM196301312680501 Surgenor, 1990, Collection and transfusion of blood in the United States, N Engl J Med:, 322, 1646, 10.1056/NEJM199006073222306 Davey, 1998, Trends in platelet utilization in Canada 1981–1987, Curr Stud Hematol Blood Transf, 54, 89, 10.1159/000415155 Kitchens, 1975, Ultrastructural changes of endothelium associated with thrombocytopenia, Blood, 46, 567, 10.1182/blood.V46.4.567.567 Aursnes, 1974, Blood platelet production and red cell leakage to lymph during thrombocytopenia, Scand J Haematol, 13, 184, 10.1111/j.1600-0609.1974.tb00258.x Hanson, 1985, Platelet kinetics in patients with bone marrow hypoplasia: evidence for a fixed platelet requirement, Blood, 66, 1105, 10.1182/blood.V66.5.1105.1105 Heal, 2004, Optimizing platelet transfusion therapy, Blood Rev, 18, 149, 10.1016/S0268-960X(03)00057-2 Beutler, 1993, Platelet transfusions: the 20,000/μL trigger, Blood, 81, 1411, 10.1182/blood.V81.6.1411.1411 Gmur, 1991, Safety of stringent prophylactic platelet transfusion policy for patients with acute leukemia, Lancet, 338, 1223, 10.1016/0140-6736(91)92098-M Heckman, 1997, Randomized study of prophylactic platelet transfusion threshold during induction therapy for adult acute leukemia: 10,000/μL versus 20,000/μL, J Clin Oncol, 15, 1143, 10.1200/JCO.1997.15.3.1143 Rebulla, 1997, The threshold for platelet transfusions in adults with acute myeloid leukemia, N Engl J Med, 337, 1870, 10.1056/NEJM199712253372602 Zumberg, 2002, A prospective randomized trial of prophylactic platelet transfusion and bleeding incidence in hematopoietic stem cell transplant recipients: 10,000/μL versus 20,000/μL trigger, Biol Blood Marrow Transplant, 8, 569, 10.1053/bbmt.2002.v8.pm12434952 Diedrich, 2005, A prospective randomized trial of prophylactic platelet transfusion trigger of 10×109 per L versus 30×109 per L in allogeneic hematopoietic progenitor transplant recipients, Transfusion, 45, 1064, 10.1111/j.1537-2995.2005.04157.x Murphy, 1992, Guidelines for platelet transfusions British Committee for standards in haematology. Working party of the blood transfusion task force, Transfus Med, 2, 311, 10.1111/j.1365-3148.1992.tb00175.x Guidelines for the use of platelet transfusions. Br J Haematol 2003;122:10–23. Schiffer, 2001, Platelet transfusion for patients with cancer: Clinical practice guidelines of the American Society of Clinical Oncology, J Clin Oncol, 19, 1519, 10.1200/JCO.2001.19.5.1519 Arnold, 2006, Utilization of platelet transfusions in the intensive care unit: indications, transfusion triggers, and platelet count responses, Transfusion, 46, 1286, 10.1111/j.1537-2995.2006.00892.x Rao, 2002, Blood component use in critically ill patients, Anaesthesia, 57, 530, 10.1046/j.1365-2044.2002.02514.x Friedmann, 2002, Do basic laboratory tests or clinical observations predict bleeding in thrombocytopenic oncology patients? A reevaluation of prophylactic platelet transfusions, Transfus Med Rev, 16, 34, 10.1053/tmrv.2002.29403 Wandt, 2006, A therapeutic platelet transfusion strategy is safe and feasible in patients after autologous peripheral blood stem cell transplantation, Bone Marrow Transplant, 37, 387, 10.1038/sj.bmt.1705246 Greeno, 2007, Platelet utilization and the transfusion trigger: a prospective analysis, Transfusion, 47, 201, 10.1111/j.1537-2995.2007.01089.x Cameron, 2007, Evaluation of platelet transfusion triggers in a tertiary care hospital, Transfusion, 47, 206, 10.1111/j.1537-2995.2007.01090.x Rinder, 1999, Optimal dosing and triggers for prophylactic use of platelet transfusions, Curr Opin Hematol, 6, 437, 10.1097/00062752-199911000-00015 Tinmouth, 2003, Prophylactic platelet transfusions: which dose is the best dose? A review of the literature, Transfus Med Rev, 17, 181, 10.1016/S0887-7963(03)00018-X Schlossberg, 2003, Platelet dosing, Transfus Apher Sci, 28, 221, 10.1016/S1473-0502(03)00039-9 Hanson, 1985, Platelet kinetics in patients with bone marrow hypoplasia: evidence for a fixed platelet requirement, Blood, 66, 1105, 10.1182/blood.V66.5.1105.1105 Klumpp, 1996, Factors associated with response to platelet transfusion following hematopoietic stem cell transplantation, Bone Marrow Transplant, 14, 1035 Norol, 1998, Platelet transfusion: a dose–response study, Blood, 92, 1448, 10.1182/blood.V92.4.1448 Hersh, 1998, Mathematical modeling of platelet survival with implications for optimal transfusion practice in the chronically platelet transfusion-dependent patient [see comments], Transfusion, 38, 637, 10.1046/j.1537-2995.1998.38798346631.x Ackerman, 2000, Economics consequences of alterations in platelet transfusion dose: analysis of a prospective, randomized, double-blind trial, Transfusion, 40, 1457, 10.1046/j.1537-2995.2000.40121457.x Allain, 2005, Protecting the blood supply from emerging pathogens: the role of pathogen inactivation, Transfus Med Rev, 19, 110, 10.1016/j.tmrv.2004.11.005 Seftel, 2004, Universal prestorage leukoreduction in Canada decreases platelet alloimmunization and refractoriness, Blood, 103, 333, 10.1182/blood-2003-03-0940 Despotis, 1999, Adverse events in platelet apheresis donors: a multivariate analysis in a hospital based program, Vox Sang, 77, 24, 10.1046/j.1423-0410.1999.7710024.x Rebulla, 1998, In vitro and in vivo properties of various types of platelets, Vox Sang, 74, 217, 10.1111/j.1423-0410.1998.tb05423.x Flegel, 1995, Low cytokine contamination in buffy coat-derived platelet concentrates without filtration, Transfusion, 35, 917, 10.1046/j.1537-2995.1995.351196110895.x Ishida, 1998, Clinical factors influencing posttransfusion platelet increment in patients undergoing hematopoietic progenitor cell transplantation – a prospective analysis, Transfusion, 38, 839, 10.1046/j.1537-2995.1998.38998409004.x Howard, 1978, The natural history of alloimmunization to platelets, Transfusion, 18, 496, 10.1046/j.1537-2995.1978.18478251250.x Kelton, 1998, ABH antigens on human platelets: expression on the glycosyl phosphatidylinositol-anchored protein CD109, J Lab Clin Med, 132, 142, 10.1016/S0022-2143(98)90009-9 Rozman, 2002, Platelet antigens: the role of human platelet alloantigens (HPA) in blood transfusion and transplantation, Transpl Immunol, 10, 165, 10.1016/S0966-3274(02)00063-1 Bishop, 1988, Clinical factors influencing the efficacy of pooled platelet transfusion, Blood, 71, 383, 10.1182/blood.V71.2.383.383 Doughty, 1994, Relative importance of immune and non-immune causes of platelet refractoriness, Vox Sang, 66, 200, 10.1111/j.1423-0410.1994.tb00310.x Novotny, 1995, Occurrence of allogeneic HLA and non-HLA antibodies after transfusion of Prestorage filtered platelets and red blood cells: a prospective study, Blood, 85, 1736, 10.1182/blood.V85.7.1736.bloodjournal8571736 Bajpai, 2005, Platelet Immunization in multitransfused patients with hemato-oncological disorders, Natl Med J Ind, 18, 134 Brandt, 1996, The mechanism of platelet aggregation induced by HLA-related antibodies, Thromb Haemost, 76, 774, 10.1055/s-0038-1650659 Eldad, 2008, Platelet transfusion refractoriness, Br J Hematol, 142, 348, 10.1111/j.1365-2141.2008.07189.x Wood, 2005, Estimation and predictive use of the corrected count increment – a proposed clinical guideline, Transfus Apher Sci, 32, 117, 10.1016/j.transci.2004.10.011 Slichter, 1997, Algorithm for managing the platelet refractory patient, J Clin Apheresis, 12, 4, 10.1002/(SICI)1098-1101(1997)12:1<4::AID-JCA2>3.0.CO;2-E Aster, 1965, Effect of anticoagulant and ABO incompatibility on recovery of transfused human platelets, Blood, 26, 732, 10.1182/blood.V26.6.732.732 Peter-Salonen, 1987, Comparison of posttransfusion recoveries achieved with either fresh or stored platelet concentrates, Blut, 54, 207, 10.1007/BF00594195 Bolgiano, 1989, A model to determine required pool size for HLA-typed community donor apheresis programs, Transfusion, 29, 306, 10.1046/j.1537-2995.1989.29489242795.x AABB Technical Manual, 14th ed. Bethesda, Md: AABB Press; 2002. Mueller-Eckhardt, 1980, HLA-C antigens on platelets, Tissue Antigens, 16, 91, 10.1111/j.1399-0039.1980.tb00291.x Messerschmidt, 1988, A prospective randomized trial of HLA-matched versus mismatched single-donor platelet transfusions in cancer patients, Cancer, 62, 795, 10.1002/1097-0142(19880815)62:4<795::AID-CNCR2820620426>3.0.CO;2-7 Schonewille, 1999, Alloimmunization after blood transfusion in patients with hematologic and oncology diseases, Transfusion, 39, 763, 10.1046/j.1537-2995.1999.39070763.x Petz, 2000, Selecting donors of platelets for refractory patients on the basis of HLA antibody specificity, Transfusion, 40, 1446, 10.1046/j.1537-2995.2000.40121446.x O’Connel, 1995, Case report: solid-phase platelet crossmatching to support the alloimmunized patient, Immunohematology, 11, 150, 10.21307/immunohematology-2019-807 Skogen, 1995, Flow cytometric analysis in platelet crossmatching using a platelet suspension immunofluorescence test, Transfusion, 35, 832, 10.1046/j.1537-2995.1995.351096026364.x Kohler, 1996, Flow cytometic detection of platelet-reactive antibodies and application in platelet crossmatching, Transfusion, 36, 250, 10.1046/j.1537-2995.1996.36396182144.x von dem Borne, 1990, Theoretic and practical aspects of platelet crossmatching, Transfus Med Rev, 4, 265, 10.1016/S0887-7963(90)70269-6 Friedberg, 1994, Independent roles for platelet crossmatching and HLA in the selection of platelets for alloimmunized patients, Transfusion, 34, 215, 10.1046/j.1537-2995.1994.34394196618.x Bertolini, 1993, Platelet quality and reductio of HLA expression in acid-treated platelet concentrates, Br J Haematol, 83, 525, 10.1111/j.1365-2141.1993.tb04684.x Novotny, 1999, The reduction of HLA class I expression on platelets: a potential approach in the management of HLA-alloimmunized refractory patients, Transfus Med Rev, 13, 95, 10.1016/S0887-7963(99)80004-2 Kleinman, 2005, The 2003a West Nile virus United States epidemic: the America’s blood centers experience, Transfusion, 45, 469, 10.1111/j.0041-1132.2005.04315.x Macedo de Oliveira, 2004, West Nile virus blod transfusion-related infection despite nucleic acid testing, Transfusion, 44, 1695, 10.1111/j.0041-1132.2004.04130.x Nash, 2001, The outbreak of West Nile virus infection in the New York City area in 1999, N Engl J Med, 344, 1807, 10.1056/NEJM200106143442401 van Rhenen, 2003, Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment: the euroSPRITE trial, Blood, 101, 2426, 10.1182/blood-2002-03-0932 Epstein, 2003, FDA approach to evaluation of pathogen reduction technology, Transfusion, 43, 1347, 10.1046/j.1537-2995.2003.00584.x Corash, 2003, Pathogen reduction technology: methods, status of clinical trials, and future aspects, Curr Hematol Rep, 2, 495 Klein, 2005, Pathogen inactivation technology: cleansing the blood supply, J Intern Med, 257, 224, 10.1111/j.1365-2796.2005.01451.x Corash, 1998, Inactivation of viruses, bacteria, protozoa, and leukocytes in platelet concentrates, Vox Sang, 74, 173, 10.1111/j.1423-0410.1998.tb05418.x Ciaravino, 2001, Preclinical safety of a nucleic acid-targeted Helinx compound: a clinical perspective, Semin Hematol, 38, 12, 10.1016/S0037-1963(01)90119-2 Ciaravino, 2001, Pharmacokinetic and toxicology assessment of INTERCEPT (S-59 and UVA treated) platelets, Hum Exp Toxicol, 20, 533, 10.1191/096032701718120319 van Rhenen, 2004, Functional characteristic of S-75. McCullough J, Vesole DH, Benjamin RJ, et al. Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT Trial, Blood, 104, 1534, 10.1182/blood-2003-12-4443 Snyder, 2004, Lin Lm, et al. Recovery and life span of 111 indium radiolabeled platelets treated with pathogen inactivation with amotosalen HCI (S-59) and ultraviolet A light, Transfusion, 44, 1732, 10.1111/j.0041-1132.2004.04145.x Ruane, 2004, Photochemical inactivation of selected viruses and bacteria in platelet concentrates using riboflavin and light, Transfusion, 44, 877, 10.1111/j.1537-2995.2004.03355.x Corbin, 2002, Pathogen inactivation of blood components: current status and introduction of an approach using riboflavin as a photo-sensitizer, Intl J Hematol, 76, 253, 10.1007/BF03165125 Aubuchon, 2005, Efficacy of apheresis platelets treated with riboflavin and ultraviolet light for pathogen reduction, Transfusion, 45, 1335, 10.1111/j.1537-2995.2005.00202.x Li, 2004, Pathogen reduction of buffy coat platelet concentrates using riboflavin and light: comparisons with pathogen-reduction technology-treated apheresis platelet products, Vox Sang, 87, 82, 10.1111/j.1423-0410.2004.00548.x